Tandem Diabetes Care, Inc.TNDMNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank86
3Y CAGR+0.9%
5Y CAGR+22.4%
Year-over-Year Change
Research and development spending
3Y CAGR
+0.9%/yr
vs +55.3%/yr prior
5Y CAGR
+22.4%/yr
Recent deceleration
Acceleration
-54.4pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
2.8x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $174.84M | -12.1% |
| 2024 | $198.88M | -19.9% |
| 2023 | $248.42M | +46.0% |
| 2022 | $170.15M | +84.8% |
| 2021 | $92.05M | +44.8% |
| 2020 | $63.57M | +40.7% |
| 2019 | $45.20M | +54.6% |
| 2018 | $29.23M | +41.5% |
| 2017 | $20.66M | +9.8% |
| 2016 | $18.81M | - |